WallStSmart

Sandisk Corp (SNDK)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 259% more annual revenue ($47.35B vs $13.18B). SNDK leads profitability with a 34.2% profit margin vs 16.0%. SNY trades at a lower P/E of 19.9x. SNDK earns a higher WallStSmart Score of 69/100 (B-).

SNDK

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 10.0Value: 3.7Quality: 8.0
Piotroski: 4/9Altman Z: 1.82

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SNDKSignificantly Overvalued (-52.4%)

Margin of Safety

-52.4%

Fair Value

$413.56

Current Price

$1096.51

$682.95 premium

UndervaluedFair: $413.56Overvalued
SNYUndervalued (+25.0%)

Margin of Safety

+25.0%

Fair Value

$62.70

Current Price

$43.35

$19.35 discount

UndervaluedFair: $62.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SNDK6 strengths · Avg: 10.0/10
Return on EquityProfitability
39.3%10/10

Every $100 of equity generates 39 in profit

Profit MarginProfitability
34.2%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
70.0%10/10

Strong operational efficiency at 70.0%

Revenue GrowthGrowth
251.0%10/10

Revenue surging 251.0% year-over-year

EPS GrowthGrowth
618.0%10/10

Earnings expanding 618.0% YoY

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$110.40B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

SNDK3 concerns · Avg: 4.0/10
P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Price/BookValuation
15.9x4/10

Trading at 15.9x book value

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.962/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : SNDK

The strongest argument for SNDK centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 34.2% and operating margin at 70.0%. Revenue growth of 251.0% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : SNDK

The primary concerns for SNDK are P/E Ratio, Price/Book, Altman Z-Score.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

SNDK profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

SNDK is growing revenue faster at 251.0% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor COMPUTER HARDWARE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SNDK scores higher overall (69/100 vs 51/100), backed by strong 34.2% margins and 251.0% revenue growth. SNY offers better value entry with a 25.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sandisk Corp

TECHNOLOGY · COMPUTER HARDWARE · USA

Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?